Novel multifunctional acyloxyalkyl ester prodrugs of 5-aminolevulinic acid display improved anticancer activity independent and dependent on photoactivation

Journal of Medicinal Chemistry

Volumn 51, Issue 23, 2008, Pages 7356-7369

  Berkovitch, Gili ^a,b   Doron, Dvir ^b   Nudelman, Abraham ^b   Malik, Zvi ^b   Rephaeli, Ada ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

1 (BUTYRYLOXY)ETHYL 5 AMINO 4 OXOPENTANOATE; AMINOLEVULINIC ACID; BUTYRIC ACID; BUTYRYLOXYMETHYL 5 AMINO 4 OXOPENTANOATE; ESTER DERIVATIVE; FORMALDEHYDE; HISTONE H2AX; MYC PROTEIN; PIVALIC ACID; PRODRUG; PROTEASOME; PROTEIN P21; PROTOPORPHYRIN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HL 60; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVATION; HEME SYNTHESIS; HUMAN; HUMAN CELL; PHOTOACTIVATION; PHOTODYNAMIC THERAPY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

AMINOLEVULINIC ACID; ANTINEOPLASTIC AGENTS; APOPTOSIS; BUTYRIC ACID; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HEME; HISTONES; HL-60 CELLS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MOLECULAR STRUCTURE; PHOSPHORYLATION; PHOTOCHEMISTRY; PORPHYRINS; PRODRUGS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-MYC; REACTIVE OXYGEN SPECIES; STEREOISOMERISM; TUMOR CELLS, CULTURED;

EID: 57349168030     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8008794     Document Type: Article

References (37)

1. Rephaeli, A.; Shaklai, M.; Ruse, M.; Nudelman, A. Derivatives of butyric acid as potential anti-neoplastic agents. Int. J. Cancer 1991, 49, 66-72.
2. Rabizadeh, E.; Shaklai, M.; Nudelman, A.; Eisenbach, L.; Rephaeli, A. Rapid alteration of c-myc and c-jun expression in leukemic cells induced to differentiate by a butyric acid prodrug. FEBS Lett. 1993, 328, 225-229.
3. Aviram, A.; Zimrah, Y.; Shaklai, M.; Nudelman, A.; Rephaeli, A. Comparison between the effect of butyric acid and its prodrug pivaloyloxymethyl butyrate on histones hyperacetylation in an HL-60 leukemic cell line. Int. J. Cancer 1994, 56, 906-909.
4. Zimra, Y.; Nudelman, A.; Zhuk, R.; Rabizadeh, E.; Shaklai, M.; Aviram, A.; Rephaeli, A. Uptake of acyloxyalkyl ester prodrugs of butyric acid into leukemic cells and their intracellular esterasecatalyzed hydrolysis. J. Cancer Res. Clin. Oncol. 2000, 123, 152-160.
5. Siu, L. L.; Von Hoff, D. D.; Rephaeli, A.; Izbicka, E.; Cerna, C.; Gomez, L.; Rowinsky, E. K.; Eckhardt, S. G. Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units. Invest. New Drugs 1998, 16, 113-119.
6. Batova, A.; Shao, L. E.; Diccianni, M. B.; Yu, A. L.; Tanaka, T.; Rephaeli, A.; Nudelman, A.; Yu, J. The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Blood 2002, 100, 3319-3324.
7. Kasukabe, T.; Rephaeli, A.; Honma, Y. An anti-cancer derivative of butyric acid (pivaloyloxymethyl-butyrate) and daunorubicin cooperatively prolong survival of mice inoculated with monocytic leukemia cells. Br. J. Cancer 1997, 75, 850-854.
8. Rephaeli, A.; Zhuk, R.; Nudelman, A. Prodrugs of butyric acid from bench to beside: synthetic design, mechanism of action, and clinical applications. Drug Dev. Res. 2000, 50, 379-391.
9. Nudelman, A.; Levovich, I.; Cutts, S. M.; Phillips, D. R.; Rephaeli, A. The role of intracellularly released formaldehyde and butyric acid in the anticancer activity of acyloxyalkyl esters. J. Med. Chem. 2005, 48, 1042-1054.
10. Levovich, I.; Nudelman, A.; Berkovitch, G.; Swift, L.; Cutts, S.; Phillips, D. R.; Rephaeli, A. Formaldehyde-releasing prodrugs specifically affect cancer cells by depletion of intracellular glutathione and augmentation of reactive oxygen species. Cancer Chemother. Pharmacol. 2008, 62, 471-482.
11. Stefan, W.; Rex, M. The heme synthesis and degradation pathways: role in oxidant sensitivity. Free Radical Biol. Med. 2000, 28, 289-309.
12. Haas, A. L.; Rose, I. A. Hemin inhibits ATP-dependent ubiquitin-dependent proteolysis: role of hemin in regulating ubiquitin conjugate degradation. Proc. Natl. Acad. Sci. U.S.A. 1981, 78, 6845-6848.
13. Etlinger, J. D.; Goldberg, A. L. Control of protein degradation in reticulocytes and reticulocyte extracts by hemin. J. Biol. Chem. 1980, 255, 4563-4568.
14. Jonathan, L.; Kaufman, L. Proteasome inhibition: novel therapy for multiple myeloma. Onkologie 2006, 29, 162-168.
15. Rodriguez, L.; Batlle, A.; Di Venosa, G.; MacRobert, A.; Battah, S.; Daniel, H.; Casas, A. Study of the mechanisms of uptake of 5-aminolevulinic acid derivatives by PEPT1 and PEPT2 transporters as a tool to improve photodynamic therapy of tumours. Int. J. Biochem. Cell Biol. 2006, 38, 1530-1539.
16. Fonseca, R.; Vianna, L.; Langeb, N.; Guyc, R.; Lopes, M.; Bentleya, B. Photodynamic therapy of skin cancer: controlled drug delivery of 5-ALA and its esters. Adv. Drug Delivery Rev. 2004, 56, 77-94.
17. Einhorn, J.; Einhorn, C.; Luche, J. L. A mild and efficient sonochemical tert-butoxycarbonylation of amines from their salts. Synlett 1991, 37-38.
18. Harada, N.; Hongu, M.; Tanaka, T.; Kawaguchi, T.; Hashiyama, T.; Tsujihara, K. A simple preparation of chloromethyl esters of the blocked amino acids. Synth. Commun. 1994, 24, 767-772.
19. Nudelman, A.; Bechor, Y.; Falb, E.; Fischer, B.; Wexler, B. A.; Nudelman, A. Acetyl chloride-methanol as a convenient reagent for: A) quantitative formation of amine hydrochlorides B), carboxylate ester formation, C) mild removal of N-t-Boc-protective group. Synth. Commun. 1998, 28, 471-474.
20. Rasmussen, M.; Leonard, N. J. Synthesis of 3-(2′-deoxy-D- ribofurancsyl)adenine. Application of a new protecting group pivaloyloxymethyl (POM). J. Am. Chem. Soc. 1967, 89, 5439-5445.
21. Yoshimura, Y.; Hamaguchi, N.; Yashiki, T. Preparation of 1-acyloxyethyl esters of 7-[2-(2-aminothiazol-4-yl)acetamido]-3-[[[1-(2-dimethylaminoethyl)- 1H-tetrazol-5-yl]thio]-methyl]ceph-3-em-4-carboxylic acid (Cefotiam) and their oral absorption in mice. J. Antibiot. 1986, 39, 1329-1342.
22. Nudelman, A.; Gnizi, E.; Katz, Y.; Azulai, R.; Cohen-Ohana, M.; Zhuk, R.; Sampson, S. R.; Langzam, L.; Fibach, E.; Prus, E.; Rephaeli, A. Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer. Eur. J. Med. Chem. 2001, 36, 63-74.
23. Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006, 58, 621-681.
24. Espunia, M. C.; Diaz, M.; Morenoa-romero, J.; Martinez, M. C. Modifications of intracellular levels of glutathione-dependent form-aldehyde dehydrogenase alters glutathione homeostasis and root development. Plant, Cell Environ. 2006, 29, 1002-1111.
25. Koivusalo, M.; Baumann, M.; Lasse, U. Evidence for the identity of glutathione-dependent formaldehyde dehydrogenase and class III alcohol dehydrogenase. FEBS Lett. 1989, 257, 105-109.
26. Kennedy, J.; Pottier, R.; Pross, G. Photodynamic therapy with endogenous protoporphyrin IX: Basic principles and present clinical experience. J. Photochem. Photobiol. B 1990, 6, 143-148.
27. Bonvini, P.; Zorzi, E.; Basso, G.; Rosolen, A. Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia 2007, 21, 838-842.
28. Boccadoro, M.; Morgan, G.; Cavenagh, J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell 2005, 5, 1-9.
29. Ding, Q.; Keller, J. N. Proteasome inhibition in oxidative stress neurotoxicity: implications for heat shock proteins. J. Neurochem. 2001, 77, 1010-1017.
30. Place, R. F.; Noonan, E. J.; Giardina, C. HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha. Biochem. Pharmacol. 2005, 70, 394-406.
31. Chen, J.; Ghazawi, F. M.; Bakkar, W.; Li, Q. Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt/protein kinase B. Mol. Cancer 2006, 5, 71-82.
32. Almond, J. B.; Snowden, R. T.; Hunter, A.; Dinsdale, D.; Cain, K.; Cohen, G. M. Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an approximately 700 kDa Apaf-1 containing apoptosome complex. Leukemia 2001, 15, 1388-1397.
33. Huang, M. J.; Cheng, Y. C.; Liu, C R.; Lin, S.; Liu, H. E. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp. Hematol. 2006, 34, 1480-1489.
34. Rogakou, E. P.; Pilch, D. R.; Orr, A. H.; Ivanova, V. S.; Bonner, W. M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 1998, 273, 5858-5868.
35. McCubrey, J. A.; Lahair, M. M.; Franklin, R. A. Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid. Redox Signaling 2006, 8, 1775-1789.
36. Shaulian, E.; Karin, M. AP-1 in cell proliferation and survival. Oncogene 2001, 20, 2390-2400.
37. Kuhn, D.; Chen, Q.; Voorhees, P.; Strader, J.; Shenk, K.; Sun, C.; Demo, S.; Bennett, M.; Leeuwen, F.; Chanan-Khan, A.; Orlowski, R. Z. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against pre-clinical models of multiple myeloma. Blood 2007, 100, 3281-3290.